Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer

ABSTRACT: Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer

PROVIDER: PRJNA306766 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer (67 not triple-negative tumors)

Project description:Recent meta-analyses suggest triple-negative breast cancer (TNBC) is a heterogenous disease. In this study we sought to define these TNBC subtypes and identify subtype-specific markers and targets. We identified and confirmed four distinct, stable TNBC subtypes: (1) Luminal-AR (LAR); 2) Mesenchymal (MES); 3) Basal-Like Immune-Suppressed (BLIS), and 4) Basal-Like Immune-Activated (BLIA).

2015-12-23 | GSE76274 | GEO

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer (198 TNBC tumors)

2015-12-18 | GSE76124 | GEO

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer (198 TNBC tumors)

2015-12-18 | E-GEOD-76124 | biostudies-arrayexpress

Comprehensive genomic analysis of CD4 T cell subtypes infiltrating human triple-negative breast cancer

Project description:Comprehensive genomic analysis of CD4 T cell subtypes infiltrating human triple-negative breast cancer

| PRJNA633781 | ENA

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-12-23 | E-GEOD-76275 | biostudies-arrayexpress

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-12-23 | GSE76275 | GEO

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Project description:Triple negative breast cancer is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study was to explore the clinical relevance of Lehmann triple negative breast cancer subtypes by identifying any differences in response to neoadjuvant chemotherapy among them.

2017-11-17 | GSE106977 | GEO

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Project description: Not available

| S-EPMC4362882 | biostudies-literature

Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors

Project description:Metaplastic breast carcinoma (MBC) is the most aggressive form of triple-negative cancer (TNBC), defined by the presence of “metaplastic” components of spindle, squamous, or sarcomatoid histology. The protein profiles underpinning the pathological subtypes and metastatic behavior of MBC are unknown. Using multiplex quantitative tandem mass tag-based proteomics we quantified 5,798 proteins in MBC, TNBC, and normal breast from 27 patients. MBC showed increased epithelial-to-mesenchymal transition and extracellular matrix, and reduced metabolic pathways compared to TNBC. MBC subtypes exhibited distinct upregulated profiles; translation and ribosomal events in spindle, inflammation and apical junctions in squamous, and extracellular matrix in sarcomatoid. Comparison of the proteomes of spindle MBC with MMTV-cre;Ccn6fl/fl spindle MBC tumors revealed a shared spindle-specific signature of 17 upregulated proteins involved in translation (e.g. RPL4,6,18, P3H1, PYCR1) and 19 downregulated proteins with roles in cell metabolism (e.g. ADH1B, ADH1C, LIPE, SOD1, FABP4). These data identify subtype specific MBC protein profiles providing biomarkers and therapeutic targets.

2020-04-22 | PXD014414 | Pride

Metabolomics Analysis of Triple Negative Breast Cancer (BCa) Cell Lines

Project description:We used untargeted metabolomic profiling to distinguish this form of BCa from estrogen receptor positive (ER+) subtypes (+/- HER2/neu) and determine that may explain why a commonly used chemotherapeutic, paclitaxel, is generally ineffective at eliciting long-term cytotoxic and/or cytostatic responses in cell line models of TNBC. This metabolomics study used broad spectrum 1H NMR to compare Luminal A (BT474, MCF-7) and triple-negative (MDA-MB-231, MDA-MB-468) BCa cell lines, to determine differences in the two subtypes as well as distinguish therapeutic treatment responses for identifying new targets for drug discovery.

2016-08-02 | ST000442 | MetabolomicsWorkbench

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data